Journal
CANCER LETTERS
Volume 372, Issue 2, Pages 192-200Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2015.12.011
Keywords
Chemokines; Therapy resistance; CXCR2; Stem cell
Categories
Funding
- Susan G. Komen for the Cure [KG090860, U54CA163120]
- National Cancer Institute, National Institutes of Health [P30CA036727]
- University of Nebraska Medical Center Graduate Student Fellowship/Assistantship
Ask authors/readers for more resources
CXCR2 and its ligands have been shown to play an important role in tumor angiogenesis, therapy resistance and progression. In this study, we investigated whether CXCR2 ligands are responsible for the survival advantage and metastasis of drug-resistant cells and examined the underlying mechanism(s) doxorubicin or paclitaxel resistant mammary tumor cells. Our results demonstrated that drug-resistant CI66 cells upregulated CXCR2 ligands but downregulated expression of CXCR2. We observed delayed tumor growth but increased metastasis in mice using these drug-resistant cells. Furthermore, we observed differential upregulation of stem cell and mesenchymal markers in the doxorubicin and paclitaxel-resistant tumor cells. Abrogation of the CXCR2 signaling axis using CXCR2 ligand neutralization resulted in significant inhibition of drug-resistant cell growth. Together, our data suggest chemotherapy-specific differential regulation of CXCR2 ligands, stem cell-like and mesenchymal phenotypes, and enhanced metastasis in drug resistant cells and targeting CXCR2 signaling, may help circumvent therapy resistance in breast cancer. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available